Across TCGA pan-cancer cohorts, ADARB2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated ADARB2 data layer compared with 20 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ADARB2 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated ADARB2 expression acts as an unfavorable survival marker, although some lineages such as LUSC and UCEC show a favorable association.
LUSC, PRAD, and LGG are the cancer types where ADARB2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.